|
1
|
de Perrot M, Licker M, Reymond MA, Robert
J and Spiliopoulos A: Influence of age on operative mortality and
long-term survival after lung resection for bronchogenic carcinoma.
Eur Respir J. 14:419–422. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chang JY, Senan S, Paul MA, Mehran RJ,
Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, et al:
Stereotactic ablative radiotherapy versus lobectomy for operable
stage I non-small-cell lung cancer: A pooled analysis of two
randomised trials. Lancet Oncol. 16:630–637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dahele M, Hatton M, Slotman B and
Guckenberger M: Stereotactic body radiotherapy: A survey of
contemporary practice in six selected European countries. Acta
Oncol. 54:1237–1241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Daly ME, Perks JR and Chen AM:
Patterns-of-care for thoracic stereotactic body radiotherapy among
practicing radiation oncologists in the United States. J Thorac
Oncol. 8:202–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang JY, Bezjak A and Mornex F: IASLC
Advanced radiation technology committee: Stereotactic ablative
radiotherapy for centrally located early stage non-small-cell lung
cancer: What we have learned. J Thorac Oncol. 10:577–585. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tree AC, Khoo VS, Eeles RA, Ahmed M,
Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ and van
As NJ: Stereotactic body radiotherapy for oligometastases. Lancet
Oncol. 14:e28–e37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Palma DA, Salama JK, Lo SS, Senan S,
Treasure T, Govindan R and Weichselbaum R: The oligometastatic
state - separating truth from wishful thinking. Nat Rev Clin Oncol.
11:549–557. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Niibe Y and Hayakawa K: Oligometastases
and oligo-recurrence: The new era of cancer therapy. Jpn J Clin
Oncol. 40:107–111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Niibe Y and Chang JY: Novel insights of
oligometastases and oligo-recurrence and review of the literature.
Pulm Med. 2012:2610962012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roesch J, Panje C, Sterzing F, Mantel F,
Nestle U, Andratschke N and Guckenberger M: SBRT for centrally
localized NSCLC- What is too central? Radiat Oncol. 11:1572016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Siegenthaler MP, Pisters KM, Merriman KW,
Roth JA, Swisher SG, Walsh GL, Vaporciyan AA, Smythe WR and Putnam
JB Jr: Preoperative chemotherapy for lung cancer does not increase
surgical morbidity. Ann Thorac Surg. 71:1105–1112. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saito M, Furukawa K, Miura T and Kato H:
Evaluation of T factor, surgical method, and prognostic factors in
central type lung cancer. Jpn J Thorac Cardiovasc Surg. 50:413–417.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Timmerman R, McGarry R, Yiannoutsos C,
Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C,
Williams M and Fletcher J: Excessive toxicity when treating central
tumors in a phase II study of stereotactic body radiation therapy
for medically inoperable early-stage lung cancer. J Clin Oncol.
24:4833–4839. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chaudhuri AA, Tang C, Binkley MS, Jin M,
Wynne JF, von Eyben R, Hara WY, Trakul N, Loo BW Jr and Diehn M:
Stereotactic ablative radiotherapy (SABR) for treatment of central
and ultra-central lung tumors. Lung Cancer. 89:50–56. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stanic S, Paulus R, Timmerman RD,
Michalski JM, Barriger RB, Bezjak A, Videtic GM and Bradley J: No
clinically significant changes in pulmonary function following
stereotactic body radiation therapy for early- stage peripheral
non-small cell lung cancer: An analysis of RTOG 0236. Int J Radiat
Oncol Biol Phys. 88:1092–1099. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Timmerman R, Paulus R, Galvin J, Michalski
J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone
D, et al: Stereotactic body radiation therapy for inoperable early
stage lung cancer. JAMA. 303:1070–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Modh A, Rimner A, Williams E, Foster A,
Shah M, Shi W, Zhang Z, Gelblum DY, Rosenzweig KE, Yorke ED, et al:
Local control and toxicity in a large cohort of central lung tumors
treated with stereotactic body radiotherapy. Int J Radiat Oncol
Biol Phys. 90:1168–1176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wheldon TE, Deehan C, Wheldon EG and
Barrett A: The linear-quadratic transformation of dose-volume
histograms in fractionated radiotherapy. Radiother Oncol.
46:285–295. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamashita H, Takahashi W, Haga A, Kida S,
Saotome N and Nakagawa K: Stereotactic body radiotherapy for small
lung tumors in the university of Tokyo hospital. Biomed Res Int.
2014:1365132014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakagawa K, Haga A, Sakumi A, Yamashita H,
Igaki H, Shiraki T, Ohtomo K, Iwai Y and Yoda K: Impact of
flattening-filter-free techniques on delivery time for lung
stereotactic volumetric modulated arc therapy and image quality of
concurrent kilovoltage cone-beam computed tomography: A preliminary
phantom study. J Radiat Res. 55:200–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamashita H, Takahashi W, Haga A and
Nakagawa K: Radiation pneumonitis after stereotactic radiation
therapy for lung cancer. World J Radiol. 6:708–715. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakagawa K, Haga A, Kida S, Masutani Y,
Yamashita H, Takahashi W, Sakumi A, Saotome N, Shiraki T, Ohtomo K,
et al: 4D registration and 4D verification of lung tumor position
for stereotactic volumetric modulated arc therapy using
respiratory-correlated cone-beam CT. J Radiat Res. 54:152–156.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lagerwaard FJ, Haasbeek CJ, Smit EF,
Slotman BJ and Senan S: Outcomes of risk-adapted fractionated
stereotactic radiotherapy for stage I non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys. 70:685–692. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thomas TO, Hasan S, Small W Jr, Herman JM,
Lock M, Kim EY, Mayr NA, Teh BS and Lo SS: The tolerance of
gastrointestinal organs to stereotactic body radiation therapy:
What do we know so far? J Gastrointest Oncol. 5:236–246.
2014.PubMed/NCBI
|
|
25
|
Stephans KL, Djemil T, Diaconu C, Reddy
CA, Xia P, Woody NM, Greskovich J, Makkar V and Videtic GM:
Esophageal dose tolerance to hypofractionated stereotactic body
radiation therapy: Risk factors for late toxicity. Int J Radiat
Oncol Biol Phys. 90:197–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pham AH, Yorke E, Rimner A and Wu AJ:
Potential for interfraction motion to increase esophageal toxicity
in lung SBRT. Technol Cancer Res Treat: 1533034617711353. 2017.
View Article : Google Scholar
|
|
27
|
Chang JY, Liu H, Balter P, Komaki R, Liao
Z, Welsh J, Mehran RJ, Roth JA and Swisher SG: Clinical outcome and
predictors of survival and pneumonitis after stereotactic ablative
radiotherapy for stage I non-small cell lung cancer. Radiat Oncol.
7:1522012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Taremi M, Hope A, Dahele M, Pearson S,
Fung S, Purdie T, Brade A, Cho J, Sun A, Bissonnette JP and Bezjak
A: Stereotactic body radiotherapy for medically inoperable lung
cancer: Prospective, single-center study of 108 consecutive
patients. Int J Radiat Oncol Biol Phys. 82:967–973. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oshiro Y, Aruga T, Tsuboi K, Marino K,
Hara R, Sanayama Y and Itami J: Stereotactic body radiotherapy for
lung tumors at the pulmonary hilum. Strahlenther Onkol.
186:274–279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bral S, Gevaert T, Linthout N, Versmessen
H, Collen C, Engels B, Verdries D, Everaert H, Christian N, De
Ridder M and Storme G: Prospective, risk-adapted strategy of
stereotactic body radiotherapy for early-stage non-small-cell lung
cancer: Results of a Phase II trial. Int J Radiat Oncol Biol Phys.
80:1343–1349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Onishi H, Araki T, Shirato H, Nagata Y,
Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, et
al: Stereotactic hypofractionated high-dose irradiation for stage I
nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in
a Japanese multiinstitutional study. Cancer. 101:1623–1631. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Andratschke N, Zimmermann F, Boehm E,
Schill S, Schoenknecht C, Thamm R, Molls M, Nieder C and Geinitz H:
Stereotactic radiotherapy of histologically proven inoperable stage
I non-small cell lung cancer: Patterns of failure. Radiother Oncol.
101:245–249. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bradley JD, El Naqa I, Drzymala RE, Trovo
M, Jones G and Denning MD: Stereotactic body radiation therapy for
early-stage non-small-cell lung cancer: The pattern of failure is
distant. Int J Radiat Oncol Biol Phys. 77:1146–1150. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rowe BP, Boffa DJ, Wilson LD, Kim AW,
Detterbeck FC and Decker RH: Stereotactic body radiotherapy for
central lung tumors. J Thorac Oncol. 7:1394–1399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Milano MT, Chen Y, Katz AW, Philip A,
Schell MC and Okunieff P: Central thoracic lesions treated with
hypofractionated stereotactic body radiotherapy. Radiother Oncol.
91:301–306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Oskan F: The quality of toxicity reporting
and the story of the lung SBRT ‘NO-FLY ZONe’. Int J Radiat Oncol
Biol Phys. 92:514–515. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Timmerman RD: The quality of toxicity
reporting and the story of the lung SBRT ‘No-Fly Zone’. In Regard
to Oskan. Int J Radiat Oncol Biol Phys. 93:726–727. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Haasbeek CJ, Lagerwaard FJ, Slotman BJ and
Senan S: Outcomes of stereotactic ablative radiotherapy for
centrally located early-stage lung cancer. J Thorac Oncol.
6:2036–2043. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chang JY, Li QQ, Xu QY, Allen PK, Rebueno
N, Gomez DR, Balter P, Komaki R, Mehran R, Swisher SG and Roth JA:
Stereotactic ablative radiation therapy for centrally located early
stage or isolated parenchymal recurrences of non-small cell lung
cancer: How to fly in a ‘no fly zone’. Int J Radiat Oncol Biol
Phys. 88:1120–1128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Q, Swanick CW, Allen PK, Gomez DR,
Welsh JW, Liao Z, Balter PA and Chang JY: Stereotactic ablative
radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell
lung cancer: Exploration of clinical indications. Radiother Oncol.
112:256–261. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Senthi S, Haasbeek CJ, Lagerwaard FJ,
Verbakel WF, de Haan PF, Slotman BJ and Senan S: Radiotherapy for a
second primary lung cancer arising post-pneumonectomy: Planning
considerations and clinical outcomes. J Thorac Dis. 5:116–122.
2013.PubMed/NCBI
|
|
42
|
Donington JS, Miller DL, Rowland CC,
Deschamps C, Allen MS, Trastek VF and Pairolero PC: Subsequent
pulmonary resection for bronchogenic carcinoma after pneumonectomy.
Ann Thorac Surg. 74:154–159. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rowell NP and Williams CJ: Radical
radiotherapy for stage I/II non-small cell lung cancer in patients
not sufficiently fit for or declining surgery (medically
inoperable): A systematic review. Thorax. 56:628–638. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lagerwaard FJ, Voet PW, van Meerbeeck JP,
Burgers SA and Senan S: Rotterdam oncological thoracic study group:
Curative radiotherapy for a second primary lung cancer arising
after pneumonectomy-techniques and results. Radiother Oncol.
62:21–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou J, Amrane S, Korkut DN, Bourdoncle A,
He HZ, Ma DL and Mergny JL: Combination of i-motif and G-quadruplex
structures within the same strand: Formation and application. Angew
Chem Int Ed Engl. 52:7742–7746. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Salmon H, Franciszkiewicz K, Damotte D,
Dieu-Nosjean MC, Validire P, Trautmann A, Mami-Chouaib F and
Donnadieu E: Matrix architecture defines the preferential
localization and migration of T cells into the stroma of human lung
tumors. J Clin Invest. 122:899–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
He HZ, Chan DS, Leung CH and Ma DL:
G-quadruplexes for luminescent sensing and logic gates. Nucleic
Acids Res. 41:4345–4359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ma DL, He HZ, Leung KH, Chan DS and Leung
CH: Bioactive luminescent transition-metal complexes for biomedical
applications. Angew Chem Int Ed Engl. 52:7666–7682. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Carretero J, Shimamura T, Rikova K,
Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA,
McNamara KL, Brandstetter KA, et al: Integrative genomic and
proteomic analyses identify targets for Lkb1-deficient metastatic
lung tumors. Cancer Cell. 17:547–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Leung CH, Zhong HJ, Yang H, Cheng Z, Chan
DS, Ma VP, Abagyan R, Wong CY and Ma DL: A metal-based inhibitor of
tumor necrosis factor-α. Angew Chem Int Ed Engl. 51:9010–9015.
2012. View Article : Google Scholar : PubMed/NCBI
|
